PharVision Advisers’s Innospec IOSP Stock Holding History

PharVision Advisers’s Portfolio IOSP Stock Details IOSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,817	Closed	-$216K	–	371
2025 Q4	$216K	Buy	+2,817	New	+$213K	0.11%	500

Other funds holding IOSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PharVision Advisers's IOSP Position: Q1 2026 in Review

PharVision Advisers sold out of Innospec (IOSP) in Q1 2026, closing a stake of 2,817 shares — an estimated $216K sold.

PharVision Advisers first reported a position in IOSP in Q4 2025 and held it in 1 quarter. The position peaked at $216K in Q4 2025. 266 funds tracked by Wall St. Rank hold IOSP as of Q1 2026.

PharVision Advisers reported no remaining Innospec position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,817 Innospec shares in Q1 2026, an estimated $216K.
PharVision Advisers first reported a position in Innospec in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Innospec position peaked at $216K in Q4 2025.
266 funds tracked by Wall St. Rank held Innospec as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.